National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Economic evaluation of Vernakalant (Brinavess®) for haemodynamically stable, symptomatic patients with atrial fibrillation of less than 48 hours duration.

Rapid Review

Commenced Completed Outcome
26/10/2010 04/11/2010 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
08/04/2011 04/05/2011 Reimbursement Recommended in Hospital Setting.

Following review, we recommend reimbursement of vernakalant in the hospital setting.

Vernakalant (Brinavess®) summary